Key Changes in MDCG 2022-4 Rev 2 for Medical Device Manufacturers
The European Commission has issued the revised MDCG 2022-4 guidance, focusing on appropriate surveillance during the transition from the Medical Devices Directive (MDD) and Active Implantable Medical Devices Directive (AIMDD) to the Medical Device Regulation (MDR).
MedNet EC-REP
Author
Let’s dive into the updates:
- Alignment with EU 2023/607: MDCG 2022-4 Rev 2 has been adjusted throughout to align with Regulation (EU) 2023/607. This regulation modifies Regulations (EU) 2017/745 and (EU) 2017/746, specifically addressing transitional provisions for certain medical devices and in vitro diagnostic medical devices.
- Legacy Device Audit Scope: Notified Body surveillance audits for MDD/AIMDD legacy devices during the MDR transition period are now explicitly outlined. Manufacturers should pay attention to this scope and ensure compliance.
Stay informed and stay compliant!
Read the full guidance here.
Related Articles
MDCG 2025-10: New PMS Guidance for MDR & IVDR
The MDCG released new PMS guidance in December 2025. Learn what MDCG 2025-10 means for your MDR and IVDR compliance strategy.
EUDAMED’s first four modules become mandatory on 28 May 2026 - what this means for medical device manufacturers
The European Commission (EC) has formally declared that the first four modules of EUDAMED - the European Database on Medical Devices - will become mandatory as of 28 May 2026.
MHRA Introduces New Device Registration Fee: What Manufacturers Need to Know
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has updated its “DORS Fees Guidance 2.1”, introducing a new annual fee model for device registration.
Stay Updated
Get the latest regulatory updates and industry insights delivered to your inbox.
Subscribe to Updates